Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021